2024-06-04 13:22:09 ET
Moderna, Inc. (MRNA)
Moderna Oncology Investor Event
June 3, 2024 07:15 PM ET
Company Participants
Stephen Hoge - President
Kyle Holen - Head of Development, Therapeutics and Oncology
Michelle Brown - Vice President, INT Oncology
Rose Loughlin - VP, R&D Strategy
Lavina Talukdar - SVP & Head of IR
Conference Call Participants
Luca Issi - RBC Capital Markets
Gena Wang - Barclays
Dina Elmonshed - Jefferies
Terence Flynn - Morgan Stanley
Jess Fye - JPMorgan
Myles Minter - William Blair
Mani Foroohar - Leerink Partners
Presentation
Stephen Hoge
We're going to get started. Thank you, everybody, for taking some time out of ASCO and your time here to spend with us. I'm Stephen Hoge, I'm the President of Moderna. And I'm going to be providing a little bit of context upfront for the data we're going to be viewing today, which will cover our full oncology pipeline. We're incredibly excited to do that.
Before I dive in, we will be making forward-looking statements during this presentation. Those are covered by the Safe Harbor Act. You can find these slides and our reference to it on our website.
Okay. So over the last number of years, we have been building a pretty extensive pipeline. Now we're going to spend almost all of our time today in oncology, focused on INT because we have some exciting data, clinical data, and obviously the presentations from today. And we're looking forward to questions on that. But we did want to take the opportunity today to give a sense of all of the other efforts that we've got advancing in clinical development, including cancer antigen-specific therapies, some novel therapeutics that have been working on actually even before INT and then some new and exciting technology partnerships that we think will translate into clinical studies very quickly here.
So our agenda for the day, we're going to try and get through relatively quickly and then get to Q&A. But we'll start off with Dr. Kyle Holen, who will walk through our overall frame for INT and how we're thinking about how it might transform cancer. We'll hand it off to Michelle Brown, who -- Dr. Michelle Brown, who leads our I&T program, and we'll run through the data that was presented by Dr. Weber at ASCO this week.
Kyle will come back and provide a little bit of voiceover on some of the other programs that we have in early clinical stage and then Dr. Rose Loughlin, who leads all of research for us in the therapeutic space, including oncology, will come and share some of our work in the external partnerships and why we're so excited about those.
So without further ado, I'll turn it over to Kyle.
Kyle Holen
Thank you, Stephen. So really excited to be here and particularly excited about talking about our oncology portfolio. The oncology portfolio has advanced in really exciting ways not just our INT program, but I'll share with you some of the advancements in the checkpoint program as well, the Triplet program....
Read the full article on Seeking Alpha
For further details see:
Moderna, Inc. (MRNA) Moderna Oncology Investor Event (Transcript)